PharVision Advisers’s IDT Corp IDT Stock Holding History

PharVision Advisers’s Portfolio IDT Stock Details IDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,166	Closed	-$213K	–	359
2025 Q4	$213K	Sell	4,166 -5,957	-59%	-$299K	0.11%	508
2025 Q3	$530K	Buy	+10,123	New	+$631K	0.3%	19

Other funds holding IDT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

KBG

Kahn Brothers Group New York $564M AUM 25.3% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

PharVision Advisers's IDT Position: Q1 2026 in Review

PharVision Advisers sold out of IDT Corp (IDT) in Q1 2026, closing a stake of 4,166 shares — an estimated $213K sold.

PharVision Advisers first reported a position in IDT in Q3 2025 and held it in 2 quarters. The position peaked at $530K in Q3 2025. 202 funds tracked by Wall St. Rank hold IDT as of Q1 2026.

PharVision Advisers reported no remaining IDT Corp position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 4,166 IDT Corp shares in Q1 2026, an estimated $213K.
PharVision Advisers first reported a position in IDT Corp in Q3 2025 and held it in 2 quarters.
PharVision Advisers's IDT Corp position peaked at $530K in Q3 2025.
202 funds tracked by Wall St. Rank held IDT Corp as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.